多肽CRO筛选: 尽职调查手册

为什么当价格领先时，肽 CRO 选择会失败

多肽CRO选择通常从报价比较开始, 这就是出错的地方. 每毫克单价是决策中最不可预测的变量, 因为它只捕获合成运行, 不是合作伙伴的方法的成本, 文档或扩大规模不成立.

故障模式的成本高昂. 一次失败的制药技术转让成本在批次成本之前超过 500 万美元, 每个工程和验证批次运行约 250 万美元，传输通常跨越 18 到 30 月, 根据 选择起源, 引用使徒行传 (2026-04-12). 将其视为供应商咨询估算, 不是经过审计的基准. 深思, 引用 CDMO Live 2025 (2025-12-15) 报告称大约一半的技术转让遇到质量问题, 并且外部转移增加了 5.8 月与内部月; 这些数字背后的基数并未披露.

要点: 低单价将成本转移到转移, 返工和延误, 其中数字大一个数量级. 下面的九个维度旨在针对这些故障模式对看起来最便宜的报价进行压力测试.

使用此作为定制肽 CRO 检查表, 不是价目表.

关于合成能力和路线的问题

该清单以一个比“你能制作我的序列吗”更尖锐的问题开始: 您将使用哪条路线, 这条路线在十倍规模下会发生什么? 固相肽合成 (统计软件) 处理大多数序列大约 50 残留物, 但链长本身并不能决定答案. 疏水性, 易于聚集的片段和非自然修饰的数量将序列推向修饰的 SPPS 或片段缩合, 每条路线都有自己的去保护和偶联策略.

索取具有相当长度和疏水性的序列的代表性批次记录, 加上随之而来的杂质概况. 这份文档比任何能力声明都能告诉您更多信息, 因为它显示了路线, 树脂, 偶联试剂和纯化基础在一起.

如果没有这些细节，已发布的规模声明就无法比较. Thermo Fisher 引用定制肽合成 0.1 毫克至 1 公斤或更多, Bachem 列出了非 GMP 肽生产 5 毫克至 100 盖特 80 到 97 纯度百分比, AAPPTec 宣传 GMP 合成量从数百毫克到数公斤不等. 在供应商说明其背后的路线和纯度基础之前，这些范围都没有任何意义.

这可以防止的故障模式是特定的: 一条干净利落的路线 50 mg 且无法缩放, 仅在您的计划已提交给合作伙伴和时间表后才发现.

如何在承诺之前测试规模灵活性

肽放大灵活性并不是供应商能力页上打印的范围. 这是一个记录在案的变更控制故事，显示了路线发生的情况, 随着批次的增长进行过程控制和发布测试.

地理是一个有用的第一过滤器, 也是一个捕捉过度行为的好地方. 按产量计算，亚太地区占全球肽原料药产能的 45-50%, with China alone at 30–35%, 根据 peptidestaff’s 2026 market review. The same source cautions that revenue and regulated-capacity distribution is more balanced, so a regional volume claim and a regulated-capacity claim are two different claims. Ask which one the vendor is actually making.

Then ask three questions: at which scale does the route change, which in-process controls are added at each step, and which release tests are added. Demand a scale-up report or comparability protocol covering milligram to gram to multi-gram. 没有它, a program can pass at lab scale and fail at the first GMP campaign.

实际需要什么修改和标签专业知识

Peptide modification services and peptide labeling and tagging are not one capability, and treating them as one is how buyers end up paying for chemistry a partner has never characterized. Noncanonical amino acid incorporation, disulfide formation and cyclization, 脂化, 聚乙二醇化, and dye, fluorophore or affinity-tag conjugation each carry separate synthesis routes, separate purification behavior and separate analytical confirmation problems. The question is not whether a vendor offers the class. It is whether the vendor has made that specific class before.

多肽合成 Ask for a prior batch record or certificate of analysis for a sequence carrying the same modification, and for the analytical method used to confirm where the modification sits. A mass shift alone tells you the conjugate formed; it does not tell you it formed at the intended residue. Without positional confirmation, isomer mixtures surface at release testing, when rework costs the most.

服务 Labeling chemistry often carries its own IP exposure, which the confidentiality questions later in this playbook pick up.

分析表征应该深入到什么程度

Peptide analytical characterization is not a question of whether a partner runs HPLC and MS, but of what the release panel detects that a purity-by-area-% figure hides. GenScript’s quality documentation notes that the area % of the target peptide is used to calculate HPLC purity (GenScript quality page, 检索到的 2026-08-03). That makes a headline “>98%” a method-dependent claim, not a universal one, because the number depends on the column, 坡度, and detection wavelength chosen.

A defensible release panel states its conditions rather than reporting a bare figure:

Validation expectations should be anchored to ICH Q2(R2), which sets out how analytical procedures are validated for their intended purpose. Ask for the actual chromatogram and mass spectrum from a representative batch, not a summary table. A purity number that cannot be reproduced under the receiving lab’s conditions is the failure mode this dimension exists to prevent.

文档, CoA 和数据完整性: 需要什么

Peptide documentation and CoA review is where most buyers stop too early. A certificate of analysis is only as useful as the data-integrity system behind it, and that system is what regulators examine when a filing is challenged.

The scale of the problem is visible in enforcement data. 一个 2026 analysis by peptidestaff counted data-integrity findings in FDA warning letters in roughly 30% of letters issued to Chinese API facilities since 2024; the reviewer’s count is stated without a disclosed sample frame, so treat it as a directional signal rather than a rate. The longer trend is firmer: 选择起源, citing FDA data for 2022, reports more than 160 FDA data-integrity warning letters between 2017 和 2022, 包括 13 在 2022 独自的.

Ask three questions of any peptide synthesis partner evaluation: Is the CoA batch-specific? Who signs it? Can audit trails be produced on request? Then hold the answers against MHRA’s ALCOA principles and a current ISO 13485 or ISO 9001 certificate.

要点: Demand a redacted, batch-specific CoA plus the audit-trail policy. A CoA that cannot be defended in a regulatory filing is a liability, not documentation.

大多数买家都会跳过知识产权处理和保密问题

Peptide IP and confidentiality exposure is wider than the sequence itself. It also covers the synthetic route, the analytical methods used to release your material, and the labeling or conjugation chemistry built on top of it. Ask four things before signing.

Who owns a route improvement discovered during the campaign? A vendor chemist who finds a better coupling or purification step may create intellectual property inside your project. The MSA should state whether that improvement belongs to you, to the vendor, or is jointly held, and under what licensing terms you can use it elsewhere.

What happens to that improvement if the relationship ends? Ownership without transfer rights is not useful. Confirm you can take the improved route, with its written procedure, to another peptide synthesis partner.

Does the proposed proprietary route carry freedom-to-operate risk? If a vendor offers a patented or proprietary route, ask who holds the patent and whether your use is covered.

How is labeling chemistry protected? Conjugation and labeling work often reveals more about your program than the peptide sequence does. Request the actual MSA and IP clauses, not a summary.

周转时间: 时间表声明真正衡量的是什么

A quoted lead time is not one number. It is four clocks running at different speeds, and vendors rarely say which one they are quoting. Synthesis lead time covers the route, the resin loading and the purification runs. Analytical release time covers method qualification, the assay panel and any repeat testing a failing specification forces. Documentation turnaround covers the CoA, the data package and the QA sign-off that makes the material releasable. Queue position decides when your project starts at all, and it is the clock most often left unstated.

Market size tells you nothing about interchangeability. 一个 2026 survey of verified peptide manufacturers mapped 241 companies across 26 or more countries, 和 119 FDA Drug Master File filings and 65 confirmed shipping to the United States. Capacity that broad still varies by route, scale and queue depth, so a shorter quote often reflects a quieter queue rather than a faster process.

Supply risk can stretch any of the four clocks after the quote is signed. Pharmaceutical-grade amino acid supply is concentrated, 与超过 80% originating from fewer than five countries. Ask each vendor which clocks their number covers, and what happens to it when a reagent shipment slips.

技术转让是一个封闭的过程, 不是一步

Peptide technology transfer is a sequence of gates, not a single handoff, and each gate needs acceptance criteria agreed before the work starts. The gates run in order: method transfer with predefined acceptance criteria, a comparability protocol, engineering batches, validation batches, and a documented method-transfer record. The cost and duration figures cited earlier describe the whole sequence, which is why treating any one gate as the finish line misreads the commitment.

The question to ask is narrow: what are the acceptance criteria for the method transfer, and who signs off that they were met? The evidence to demand is a completed method-transfer record from a prior program, not a summary of one. That record shows whether the receiving lab reproduced the assay under its own hands, which is the only proof that matters.

对于小费: Write the acceptance criteria before the transfer begins. Criteria negotiated after the first data set arrives tend to bend toward whatever the lab produced.

这可以防止的故障模式是特定的: a transfer declared complete before the receiving lab can reproduce the assay. Once that declaration is signed, the discrepancy surfaces later as a batch failure with no clean owner.

九个维度的评分: 比较矩阵

The nine dimensions only become a decision tool once you weight them, and the first thing a custom peptide CRO checklist has to normalize is scope. Published market figures disagree because they measure different things: a wider-definition peptide CDMO figure puts the market at USD 4.59B in 2025 rising to USD 5.52B in 2026 at a 20.3% 复合年增长率 (Pharma Manufacturing, 2026-08-19), while a combined peptide and oligonucleotide CDMO figure gives USD 2.68B in 2025 and USD 2.98B in 2026 在 11.05% (Mordor Intelligence, 2026-07-31). Vendor claims inherit the same problem. Score each dimension 1 到 5, then apply stage weights: discovery favors route flexibility and speed, clinical favors analytical characterization and documentation, commercial favors scale and technology transfer. Treat data integrity, IP terms and transferability as disqualifying rather than low-scoring.

完整证据包的工作示例

The fastest way to calibrate your scoring is to request one representative package and read it end to end. Ask for a completed program, not a template: a synthesis route with the impurity rationale behind it, release and stability data on the same lot, a method transfer report with acceptance criteria and the actual results, and a CoA whose raw data are retrievable.

One example of what to ask for is the analytical and transfer documentation MOL Changes can be used to request as a representative package. Treat it as a benchmark rather than a recommendation, and score it against the same nine dimensions you apply elsewhere.

Then check replicability. If the package answers your questions but cannot be re-run by a second lab from the written record alone, it documents an outcome rather than a process. A complete submission lets your own team reproduce the result, which is the standard peptide CRO selection should be held to.

肽合作伙伴评估中的常见错误

Comparing vendors on price per milligram without a purity basis. A quote of $X per milligram means little until you know whether it is priced on crude, purified, or net-peptide basis, and at what scale and route. The fix is to normalize every quote to the same purity specification, the same scale, and the same synthesis route before you compare. Otherwise the cheapest number is often the one with the least material behind it.

Accepting a capability claim without a batch record. Anyone can say they run difficult sequences. Ask for a redacted batch record from a comparable program: the actual yields, the purification steps, the analytical results. If they cannot show one, treat the claim as unverified.

Treating peptide technology transfer as a formality. Transfer is a gated process with acceptance criteria, not a handover email. Build the gates into the timeline and the contract.

Accepting a summary CoA instead of a batch-specific one. A generic certificate tells you what the vendor can do, not what you received. Demand the batch-specific document.

Assuming a quoted lead time covers documentation and release. The synthesis date is not the release date. Ask what the quote includes and what it excludes.

常见问题解答

我可以在没有现场审核的情况下评估肽 CRO吗?

Yes for early screening, no for a GMP commitment. A batch-specific certificate of analysis, a completed method-transfer record, the audit-trail policy for the chromatography data system, and current quality-system certification (国际标准化组织 13485 或同等水平) let you judge most of what a site visit would show. What they cannot replace is direct observation of material flow, segregation of quarantined batches, and how operators actually handle deviations. Treat peptide CRO selection as a two-stage decision: documents for the shortlist, an audit before you sign a GMP supply agreement.

如果方法转移未达到验收标准，我该怎么办?

Stop the transfer and document the deviation before anything else. Then agree with the partner on a root-cause investigation covering the method, the equipment, and the analyst, and re-run against the same predefined acceptance criteria. Do not renegotiate the criteria to make the second attempt pass. If the failure traces to the receiving laboratory rather than the method, that is a finding about the partner’s capability, not a reason to loosen the specification.

这个框架如何在商业规模上发生变化?

Dimensions that were merely preferred earlier become disqualifying. Scale flexibility and documentation completeness carry the most weight, because peptide technology transfer to commercial supply leaves little room for a partner who cannot demonstrate the route at the volumes you will need or produce records that survive regulatory inspection. Analytical depth also shifts from a differentiator to a baseline expectation.

更长的交货时间是更好的选择吗?

是的, when the shorter quote excludes documentation, 发布测试, or queue risk. Compare timelines like for like: ask what is included in the stated window, whether release testing runs inside or after it, and how the partner handles a queue that slips. A quote that looks three weeks faster often ends up slower once those items are added back.

结论和后续步骤

You now have a nine-dimension framework for peptide CRO selection: synthesis capability and route, scale flexibility, modification and labeling expertise, 分析深度, documentation and CoA practice, IP handling, turnaround reality, and technology transfer as a gated process. Two of those dimensions, peptide documentation and CoA integrity and peptide technology transfer, are disqualifying rather than merely low-scoring. A partner that fails them cannot be rescued by a lower quote.

That is the reframe worth keeping. Price per milligram is an output of the criteria you apply, not the criteria themselves. The dimensions that decide whether a program survives a filing are also the ones that are hardest to compare across vendors, which is why the scoring matrix matters more than the quote sheet.

Score your shortlist against the same nine dimensions Request a representative analytical and transfer package and score it against the checklist in this guide, exactly as you would score any other vendor. Request a representative analytical package

Disclosure: MOL Changes publishes as a peptide vendor with a commercial interest in peptide quality standards.